Potential Overestimation of Racial Disparities in Response to the 8-Week Ledipasvir/Sofosbuvir Regimen for Hepatitis C Virus Genotype 1 Infection

Gastroenterology. 2018 Nov;155(5):1646-1647.e2. doi: 10.1053/j.gastro.2018.07.044. Epub 2018 Aug 15.

Authors

Rohit P Ojha¹, Brooke R MacDonald², Tzu-Chun Chu², Julia L Marcus³

Affiliations

¹ Center for Outcomes Research, JPS Health Network and Department of Biostatistics and Epidemiology, UNT Health Science Center, Fort Worth, Texas.
² Center for Outcomes Research, JPS Health Network, Fort Worth, Texas.
³ Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Antiviral Agents / administration & dosage*
Benzimidazoles / administration & dosage*
Drug Therapy, Combination
Fluorenes / administration & dosage*
Genotype
Health Status Disparities
Hepacivirus / classification
Hepacivirus / genetics
Hepatitis C / drug therapy*
Hepatitis C / ethnology
Hepatitis C / virology
Humans
Sofosbuvir / administration & dosage*

Substances

Antiviral Agents
Benzimidazoles
Fluorenes
ledipasvir
Sofosbuvir

Grants and funding

K01 AI122853/AI/NIAID NIH HHS/United States